LFVNHIGH SIGNALOPPORTUNITY10-K

LFVN achieved exceptional profitability improvement with net income surging 234% alongside strategic launch of the patent-pending MindBody GLP-1 System targeting the high-growth weight management market.

The company's pivot into GLP-1-related products positions it to capitalize on the massive weight management trend while demonstrating strong execution with dramatically improved profitability. The 100% increase in R&D spending signals serious investment in innovation, particularly around the new GLP-1 system that could drive significant revenue growth.

Comparing 2025-09-04 vs 2024-08-28View on EDGAR →
FINANCIAL ANALYSIS

LFVN delivered outstanding financial performance with net income jumping 234% to $9.8M and operating income increasing 182% to $12.2M, demonstrating strong operational leverage. The company strengthened its balance sheet with stockholders' equity rising 33% and current assets growing 35%, while strategically building inventory (+37%) likely to support the new GLP-1 product launch. Despite higher interest expense and doubled R&D spending reflecting growth investments, the company reduced shareholder returns (dividends down 70%, buybacks down 51%) to preserve cash for expansion, signaling management confidence in reinvestment opportunities.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+233.8%
$2.9M$9.8M

Net income grew 233.8% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+181.6%
$4.3M$12.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
-117.2%
-$198K-$430K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

R&D Expense
P&L
+100%
$700K$1.4M

R&D investment increased 100% — signals commitment to future product development, though near-term margin impact.

Dividends Paid
Cash Flow
-70.2%
$6.9M$2.1M

Dividends cut 70.2% — significant signal of cash flow stress or capital reallocation priorities.

Share Buybacks
Cash Flow
-51.1%
$6.4M$3.1M

Buyback activity reduced 51.1% — capital being redeployed elsewhere or cash conservation underway.

Capital Expenditure
Cash Flow
-38.9%
$2.2M$1.4M

Capex reduced 38.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Inventory
Balance Sheet
+37.3%
$15.1M$20.7M

Inventory surged 37.3% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+35.2%
$37.6M$50.9M

Current assets grew 35.2% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+33.3%
$26.0M$34.6M

Equity base grew 33.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2025-09-04
PRIOR — 2024-08-28
ADDED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Exhibits, Financial Statement Schedules 57 Signatures 60 5 PART I ITEM 1 BUSINESS Overview LifeVantage Corporation (the Company, LifeVantage, we, us, or our ) is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.
We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics.
Our product lines include: Protandim , our flagship line of scientifically validated dietary supplements; LifeVantage , our line of dietary supplements that include the MindBody GLP-1 System , Omega+, ProBio, IC Bright , the Rise AM Reset PM System , D3+, and Daily Wellness; PhysIQ , our Fat Burn and Prebiotic dietary supplements; TrueScience , our line of skin and hair care products and Liquid Collagen; Petandim , our companion pet supplement formulated to combat oxidative stress in dogs; and AXIO , our nootropic energy drink mixes.
Fiscal Year 2025 Highlights New Product Offerings In fiscal year 2025, we launched the next evolution in activation, the patent-pending MindBody GLP-1 System consisting of MB Core and MB Enhance .
+7 more — sign up free →
REMOVED
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Exhibits, Financial Statement Schedules 56 Signatures 59 5 PART I ITEM 1 BUSINESS Overview LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health.
We engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products.
Our line of scientifically validated dietary supplements includes our flagship Protandim family of products, LifeVantage Omega+, ProBio, IC Bright , Rise AM, Reset PM, D3+, Daily Wellness, and PhysIQ Fat Burn and Prebiotic dietary supplements.
TrueScience is our line of skin and hair care products and Liquid Collagen.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →